Industry Growth Insights published a new data on “Injectable Drug Delivery Formulation Market”. The research report is titled “Injectable Drug Delivery Formulation Market research by Types (Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations, Long-acting Formulations), By Applications (Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Others), By Players/Companies Becton, Dickinson and Company (US), Baxter International Inc. (US), Gerresheimer AG (Germany), Pfizer, Inc. (US), Schott AG (Germany), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), Becton, Dickinson and Company (US)”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Injectable Drug Delivery Formulation Market Research Report
By Type
Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations, Long-acting Formulations
By Application
Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Others
By Companies
Becton, Dickinson and Company (US), Baxter International Inc. (US), Gerresheimer AG (Germany), Pfizer, Inc. (US), Schott AG (Germany), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), Becton, Dickinson and Company (US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Injectable Drug Delivery Formulation Market Report Segments:
The global Injectable Drug Delivery Formulation market is segmented on the basis of:
Types
Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations, Long-acting Formulations
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Becton, Dickinson and Company (US)
- Baxter International Inc. (US)
- Gerresheimer AG (Germany)
- Pfizer, Inc. (US)
- Schott AG (Germany)
- Sandoz (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Eli Lilly and Company (US)
- Becton, Dickinson and Company (US)
Highlights of The Injectable Drug Delivery Formulation Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Conventional Drug Delivery Formulations
- Novel Drug Delivery Formulations
- Long-acting Formulations
- By Application:
- Autoimmune Diseases
- Hormonal Disorders
- Oncology
- Orphan Diseases
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Injectable Drug Delivery Formulation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Injectable drug delivery formulation is a specialized form of pharmaceuticals that are delivered directly into the bloodstream through an injection.
Some of the key players operating in the injectable drug delivery formulation market are Becton, Dickinson and Company (US), Baxter International Inc. (US), Gerresheimer AG (Germany), Pfizer, Inc. (US), Schott AG (Germany), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), Becton, Dickinson and Company (US).
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Injectable Drug Delivery Formulation Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Injectable Drug Delivery Formulation Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Injectable Drug Delivery Formulation Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Injectable Drug Delivery Formulation Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Injectable Drug Delivery Formulation Market Size & Forecast, 2020-2028
4.5.1 Injectable Drug Delivery Formulation Market Size and Y-o-Y Growth
4.5.2 Injectable Drug Delivery Formulation Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Conventional Drug Delivery Formulations
5.2.2 Novel Drug Delivery Formulations
5.2.3 Long-acting Formulations
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Autoimmune Diseases
6.2.2 Hormonal Disorders
6.2.3 Oncology
6.2.4 Orphan Diseases
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Injectable Drug Delivery Formulation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Injectable Drug Delivery Formulation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Conventional Drug Delivery Formulations
9.6.2 Novel Drug Delivery Formulations
9.6.3 Long-acting Formulations
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Autoimmune Diseases
9.10.2 Hormonal Disorders
9.10.3 Oncology
9.10.4 Orphan Diseases
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Conventional Drug Delivery Formulations
10.6.2 Novel Drug Delivery Formulations
10.6.3 Long-acting Formulations
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Autoimmune Diseases
10.10.2 Hormonal Disorders
10.10.3 Oncology
10.10.4 Orphan Diseases
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Conventional Drug Delivery Formulations
11.6.2 Novel Drug Delivery Formulations
11.6.3 Long-acting Formulations
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Autoimmune Diseases
11.10.2 Hormonal Disorders
11.10.3 Oncology
11.10.4 Orphan Diseases
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Conventional Drug Delivery Formulations
12.6.2 Novel Drug Delivery Formulations
12.6.3 Long-acting Formulations
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Autoimmune Diseases
12.10.2 Hormonal Disorders
12.10.3 Oncology
12.10.4 Orphan Diseases
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Conventional Drug Delivery Formulations
13.6.2 Novel Drug Delivery Formulations
13.6.3 Long-acting Formulations
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Autoimmune Diseases
13.10.2 Hormonal Disorders
13.10.3 Oncology
13.10.4 Orphan Diseases
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Injectable Drug Delivery Formulation Market: Competitive Dashboard
14.2 Global Injectable Drug Delivery Formulation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Becton, Dickinson and Company (US)
14.3.2 Baxter International Inc. (US)
14.3.3 Gerresheimer AG (Germany)
14.3.4 Pfizer, Inc. (US)
14.3.5 Schott AG (Germany)
14.3.6 Sandoz (Germany)
14.3.7 Teva Pharmaceutical Industries Ltd. (Israel)
14.3.8 Eli Lilly and Company (US)
14.3.9 Becton, Dickinson and Company (US)
